American Thoracic Society International Conference

American Thoracic Society International Conference

Source:

Ferguson GT, et al. B93 – Late Breaking Clinical Trials in Airway Diseases. Presented at: American Thoracic Society Virtual; Aug. 5-10, 2020 (virtual meeting).

Disclosures: This study was funded by Verona Pharma. Healio could not confirm relevant financial disclosures at the time of publication.
August 24, 2020
2 min read
Save

Ensifentrine plus tiotropium improves lung function, quality of life in patients with COPD

Source:

Ferguson GT, et al. B93 – Late Breaking Clinical Trials in Airway Diseases. Presented at: American Thoracic Society Virtual; Aug. 5-10, 2020 (virtual meeting).

Disclosures: This study was funded by Verona Pharma. Healio could not confirm relevant financial disclosures at the time of publication.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Adding ensifentrine to tiotropium demonstrated clinically important improvements in lung function and quality of life at 4 weeks in patients with moderate to severe COPD, according to a new study.

Gary T. Ferguson, MD, pulmonologist at the Pulmonary Research Institute of Southeast Michigan, and colleagues reported data from a phase 2, double-blind, placebo-controlled, parallel-group, dose-ranging study of twice-daily nebulized ensifentrine (Verona Pharma) added to once-daily tiotropium (Spiriva Respimat, Boehringer Ingelheim) in an e-poster presented at the American Thoracic Society Virtual meeting.

COPD
Source: Adobe Stock.

Researchers previously completed a placebo-controlled, dose-ranging phase 2 study that showed ensifentrine improved lung function and reduced symptoms in patients with moderate to severe COPD.

In this current study, researchers enrolled 416 patients (mean age, 64.3 years; 42.5% men) with COPD who were current and former smokers ( 10 pack-year history). Enrolled patients remained symptomatic with FEV1 30% to 70% predicted following treatment with tiotropium. Patients were randomly assigned to once-daily tiotropium plus nebulized ensifentrine at one of four doses (0.375 mg, 0.75 mg, 1.5 mg or 3 mg) or placebo twice daily. Spirometry was performed before dosing and over 3 or 12 hours.

Primary endpoint was change from baseline in peak FEV1 at 4 weeks. Other endpoints included average FEV1 over 3 and 12 hours, COPD-related quality of life and safety.

All ensifentrine doses demonstrated significant bronchodilation in addition to tiotropium with a dose-dependent increase from baseline FEV1 at 4 weeks (78 mL to 124 mL; P < .05 for all).

Researchers observed dose-dependent increases in average FEV1 with ensifentrine 3 mg, with an increase to 87 mL (P = .0111). Patient responses to the St. George’s Respiratory Questionnaire showed clinically meaningful and statistically significant improvement in quality of life exceeding 4 U at 4 weeks with ensifentrine 1.5 mg and 3 mg (P < .05 for both).

Adverse events were similar across all groups.

“These data support progression of ensifentrine to phase 3 as a maintenance treatment for COPD,” the researchers wrote in the study abstract.

Ensifentrine is a first-in-class, inhaled dual phosphodiesterase 3/4 inhibitor that combines bronchodilator and anti-inflammatory actions in a single compound.

According to a press release from Verona Pharma, preparations for the phase 3 clinical programs are underway following response from the FDA and are expected to begin in late 2020. The two studies, ENHANCE-1 and ENHANCE-2, will assess the safety and efficacy of twice-daily nebulized ensifentrine as monotherapy and as an add-on to standard treatment with a single bronchodilator, a long-acting muscarinic antagonist or a long-acting beta agonist.

Reference: